Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors-Reference-Cited by-同舟云学术

Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors

Published:2010 Issue: Volume: Page:n/a-n/a
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Festuccia Claudio,Dondi Donatella,Piccolella Margherita,Locatelli Alessia,Gravina Giovanni Luca,Tombolini Vincenzo,Motta Marcella

Publisher

Wiley

Subject

Urology,Oncology

Reference41 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer;Wagner;Urology,2005

3. Endocrine therapy of prostate cancer;Bare;Cancer Treat Res,1998

4. New endocrine approaches in the treatment of breast cancer;Von Minckwitz;Biomed Pharmacother,1998

5. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists;Redding;J Endocrinol,1990

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives;Frontiers in Molecular Biosciences;2021-06-14

2. Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions;International Journal of Molecular Sciences;2020-12-14

3. The discovery of potent and stable short peptide FGFR1 antagonist for cancer therapy;European Journal of Pharmaceutical Sciences;2020-02

4. Down‐regulation of intracellular anti‐apoptotic proteins, particularly c‐FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL;Journal of Cellular Physiology;2018-05-09

5. Emerging drugs for the treatment of benign prostatic hyperplasia;Expert Opinion on Emerging Drugs;2017-07-03